COMPARATIVE STUDY ON SAFETY & EFFICACY OF ESCITALOPRAM VS VORTIOXETINE IN DEPRESSION DISORDER

Aims: The aim of the study is comparing the safety and efficacy of SSRI’S (Escitalopram) and serotonin receptor modulator (vortioxetine) in depressive patients. Objectives: To assess the relative efficacy and safety of Escitalopram. Safety and efficacy of Vortioxetine in depressive patients. To analyse the age, gender and socio demographic data. Methodology: The study will be conducted at Maurya Hospital, Kurnool, over six months as a prospective observational study. It will involve 50-100 patients, with data collected through patient forms and interviews. Participants must be aged 18-60, diagnosed with depression, and prescribed Escitalopram or Vortioxetine, with voluntary consent. Excluded are those unwilling to participate, on psychotropic medications, or diagnosed with schizophrenia or bipolar disorder. Discussion: A study on 60 depression patients compared Escitalopram (Group A) and Vortioxetine (Group B). Both groups had similar age and gender distributions. Group A showed higher depression severity and burnout, while Group B had slightly higher compassion scores. Both treatments significantly improved depression scores, with Group B showing greater reductions in burnout and secondary traumatic stress. The findings indicate effectiveness for both medications, with differences in psychological outcomes. Conclusion: The study compared 60 patients on Escitalopram (Group A) and Vortioxetine (Group B). Group A had higher initial depression and burnout, while Group B showed more compassion. Both groups improved in HAM-D scores, with Group A reducing burnout and traumatic stress, and Group B experiencing declines in overall quality of life scores. Both treatments were effective.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-06-16
DOI
https://doi.org/10.5281/zenodo.20698674
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

COMPARATIVE STUDY ON SAFETY & EFFICACY OF ESCITALOPRAM VS VORTIOXETINE IN DEPRESSION DISORDER

*Dr. Perumala Jasmine Joy, Dr. G. Vinod, Dr. K. Jagadeesh, Dr. K. Hari Prasad, Dr. N. M. Vageesh
Zenodo (CERN European Organization for Nuclear Research)
Treatment of Major Depression
article

COMPARATIVE STUDY ON SAFETY & EFFICACY OF ESCITALOPRAM VS VORTIOXETINE IN DEPRESSION DISORDER

*Dr. Perumala Jasmine Joy, Dr. G. Vinod, Dr. K. Jagadeesh, Dr. K. Hari Prasad, Dr. N. M. Vageesh
article en

Abstract

Aims: The aim of the study is comparing the safety and efficacy of SSRI’S (Escitalopram) and serotonin receptor modulator (vortioxetine) in depressive patients. Objectives: To assess the relative efficacy and safety of Escitalopram. Safety and efficacy of Vortioxetine in depressive patients. To analyse the age, gender and socio demographic data. Methodology: The study will be conducted at Maurya Hospital, Kurnool, over six months as a prospective observational study. It will involve 50-100 patients, with data collected through patient forms and interviews. Participants must be aged 18-60, diagnosed with depression, and prescribed Escitalopram or Vortioxetine, with voluntary consent. Excluded are those unwilling to participate, on psychotropic medications, or diagnosed with schizophrenia or bipolar disorder. Discussion: A study on 60 depression patients compared Escitalopram (Group A) and Vortioxetine (Group B). Both groups had similar age and gender distributions. Group A showed higher depression severity and burnout, while Group B had slightly higher compassion scores. Both treatments significantly improved depression scores, with Group B showing greater reductions in burnout and secondary traumatic stress. The findings indicate effectiveness for both medications, with differences in psychological outcomes. Conclusion: The study compared 60 patients on Escitalopram (Group A) and Vortioxetine (Group B). Group A had higher initial depression and burnout, while Group B showed more compassion. Both groups improved in HAM-D scores, with Group A reducing burnout and traumatic stress, and Group B experiencing declines in overall quality of life scores. Both treatments were effective.

Zenodo (CERN European Organization for Nuclear Research)
Gender equality
Openalex Percentile: Top 10%
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

COMPARATIVE STUDY ON SAFETY & EFFICACY OF ESCITALOPRAM VS VORTIOXETINE IN DEPRESSION DISORDER — *Dr. Perumala Jasmine Joy, Dr. G. Vinod, Dr. K. Jagadeesh, Dr. K. Hari Prasad, Dr. N. M. Vageesh · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS